[Market Focus] Nature Cell Hits Upper Limit on Hopes for FDA Approval

On April 22, shares of Nature Cell hit the upper price limit on expectations that the U.S. Food and Drug Administration (FDA) may approve its stem cell therapy for degenerative arthritis, following the results of its Phase 3 clinical trial.

As of 1:32 p.m. on this day, Nature Cell was trading at 33,250 won, up 7,650 won (29.88%) from the previous session. The stock also reached a new 52-week high.

Previously, it was reported that the FDA determined the Phase 3 clinical trial of JointStem, conducted by Nature Cell in Korea, met the final clinical trial standards required for approval review in the United States.

Following this news, expectations spread in the market that Nature Cell could apply for approval of JointStem with only a small-scale supplementary clinical trial to complement the domestic Phase 3 trial.